Efficacy and Safety of Telaglenastat Plus Cabozantinib vs Placebo Plus Cabozantinib in Patients With Advanced RCC
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Efficacy and Safety of Telaglenastat Plus Cabozantinib vs Placebo Plus Cabozantinib in Patients With Advanced Renal Cell Carcinoma: The CANTATA Randomized Clinical Trial
JAMA Oncol 2022 Sep 01;[EPub Ahead of Print], NM Tannir, N Agarwal, C Porta, NJ Lawrence, R Motzer, B McGregor, RJ Lee, RK Jain, N Davis, LJ Appleman, O Goodman, WM Stadler, S Gandhi, DM Geynisman, R Iacovelli, B Mellado, JM Sepúlveda Sánchez, R Figlin, T Powles, L Akella, K Orford, B EscudierFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.